
Duloxetine (30mg) + Pregabalin (75mg)
Active composition
+1 more active ingredient
Pregabalin binds to the alpha-2-delta subunit of voltage-gated calcium channels, inhibiting excitatory neurotransmitter release and reducing neuronal excitability.
Medical applications
Maxdulin 75/30 Capsule DR is a combination pharmaceutical formulation containing Pregabalin 75 mg and Duloxetine 30 mg, designed for the management of neuropathic pain and certain mood disorders. Pregabalin, an anticonvulsant and analgesic agent, modulates calcium channels in the central nervous system, reducing neurotransmitter release and thereby alleviating neuropathic pain symptoms such as burning, shooting pain, and allodynia. Duloxetine, a selective serotonin and norepinephrine reuptake inhibitor (SNRI), enhances the inhibitory pain pathways and is effective in treating major depressive disorder and generalized anxiety disorder, in addition to its analgesic properties. The delayed-release (DR) formulation ensures gradual drug release, improving tolerability and maintaining therapeutic plasma concentrations over an extended period. Maxdulin 75/30 is indicated for patients requiring combined therapy for chronic neuropathic pain conditions, including diabetic peripheral neuropathy and fibromyalgia, especially when accompanied by depressive symptoms. The combination targets multiple pain pathways, offering enhanced efficacy compared to monotherapy. Caution is advised in patients with hepatic or renal impairment, and potential side effects include dizziness, somnolence, dry mouth, and gastrointestinal disturbances. This medication should be prescribed and monitored by healthcare professionals to optimize therapeutic outcomes and minimize adverse effects.
Dosage information not available. Please consult your doctor or pharmacist.
Important precautions
Based on clinical trials and patient reports.
Overall Tolerance
Common Side Effects
Maxdulin 75/30 Capsule DR may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Please consult your doctor.
High Risk
Maxdulin 75/30 Capsule DR is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.
Medical Advice
Maxdulin 75/30 Capsule DR should be used with caution in patients with kidney disease. Dose adjustment of Maxdulin 75/30 Capsule DR may be needed. Please consult your doctor.
Exercise Caution
Maxdulin 75/30 Capsule DR may decrease alertness, affect your vision or make you feel sleepy and dizzy. Do not drive if these symptoms occur.
Consult Doctor
Maxdulin 75/30 Capsule DR is probably unsafe to use in patients with liver disease and should be avoided. Please consult your doctor.
Regular Checkup
0 reviews for Maxdulin 75/30 Capsule DR

Pregabalin (75mg) + Duloxetine (30mg)
Cheaper alternative availability
This medicine doesn't have a cheaper alternative with the same composition. Our health advisors can help you find other savings options based on your prescription.
Active composition
+1 more active ingredient
Pregabalin binds to the alpha-2-delta subunit of voltage-gated calcium channels, inhibiting excitatory neurotransmitter release and reducing neuronal excitability.
Medical applications
Maxdulin 75/30 Capsule DR is a combination pharmaceutical formulation containing Pregabalin 75 mg and Duloxetine 30 mg, designed for the management of neuropathic pain and certain mood disorders. Pregabalin, an anticonvulsant and analgesic agent, modulates calcium channels in the central nervous system, reducing neurotransmitter release and thereby alleviating neuropathic pain symptoms such as burning, shooting pain, and allodynia. Duloxetine, a selective serotonin and norepinephrine reuptake inhibitor (SNRI), enhances the inhibitory pain pathways and is effective in treating major depressive disorder and generalized anxiety disorder, in addition to its analgesic properties. The delayed-release (DR) formulation ensures gradual drug release, improving tolerability and maintaining therapeutic plasma concentrations over an extended period. Maxdulin 75/30 is indicated for patients requiring combined therapy for chronic neuropathic pain conditions, including diabetic peripheral neuropathy and fibromyalgia, especially when accompanied by depressive symptoms. The combination targets multiple pain pathways, offering enhanced efficacy compared to monotherapy. Caution is advised in patients with hepatic or renal impairment, and potential side effects include dizziness, somnolence, dry mouth, and gastrointestinal disturbances. This medication should be prescribed and monitored by healthcare professionals to optimize therapeutic outcomes and minimize adverse effects.
Dosage information not available. Please consult your doctor or pharmacist.
Important precautions
Based on clinical trials and patient reports.
Overall Tolerance
Common Side Effects
Maxdulin 75/30 Capsule DR may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Please consult your doctor.
High Risk
Maxdulin 75/30 Capsule DR is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.
Medical Advice
Maxdulin 75/30 Capsule DR should be used with caution in patients with kidney disease. Dose adjustment of Maxdulin 75/30 Capsule DR may be needed. Please consult your doctor.
Exercise Caution
Maxdulin 75/30 Capsule DR may decrease alertness, affect your vision or make you feel sleepy and dizzy. Do not drive if these symptoms occur.
Consult Doctor
Maxdulin 75/30 Capsule DR is probably unsafe to use in patients with liver disease and should be avoided. Please consult your doctor.
Regular Checkup
0 reviews for Maxdulin 75/30 Capsule DR















